WGS: advancing Waldenström’s diagnosis, prognosis & treatment

WGS: advancing Waldenström’s diagnosis, prognosis & treatment

VJHemOnc

1 year
138 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The discovery of mutational events in cancer are crucial to the development of efficacious targeted therapies. Here, Steven Treon, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, passionately discusses the genomic advances in Waldenströms macroglobulinemia (WM), owing to the discovery of the MYD88 and CXCR4 mutations. Dr Treon highlights how these mutations have enabled better understanding of the different forms and metastatic progression of WM, aiding the development of targeted therapies that are revolutionizing the meaning of progression-free survival. This interview was recorded at the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy.
Up Next Autoplay
Comparative Outcomes of Relapsed Follicular Lymphoma Patients #ASH19 @ClevelandClinic
Comparative Outcomes of Relapsed Follicular Lymphoma Patients #ASH19 @ClevelandClinic
Category: Non-Hodgkin Lymphoma
26 Views
ash 4 weeks
Analysis of Brentuximab Vedotin Plus  CHP (A+CHP) #ASH19 @OfficialUoM
Analysis of Brentuximab Vedotin Plus CHP (A+CHP) #ASH19 @OfficialUoM
Category: Non-Hodgkin Lymphoma
5 Views
ash 1 month
Follow-Up in Relapsed/Refractory MCL #ASH19
Follow-Up in Relapsed/Refractory MCL #ASH19
Category: Non-Hodgkin Lymphoma
20 Views
ash 1 month
Dose Optimization Portion of the Phase 2 PRIMO Study in Relapsed or Refractory PTCL #ASH19 @sloan_kettering
Dose Optimization Portion of the Phase 2 PRIMO Study in Relapsed or Refractory PTCL #ASH19 @sloan_kettering
Category: Non-Hodgkin Lymphoma
31 Views
ash 1 month
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy #ASH19
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy #ASH19
Category: Non-Hodgkin Lymphoma
4 Views
ash 1 month
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Category: Non-Hodgkin Lymphoma
7 Views
Cancer-News 1 month
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Category: Non-Hodgkin Lymphoma
3 Views
Cancer-News 1 month
Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer
Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer
Category: Non-Hodgkin Lymphoma
10 Views
ash 1 month
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Category: Non-Hodgkin Lymphoma
27 Views
Cancer-News 1 month
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Category: Non-Hodgkin Lymphoma
6 Views
Cancer-News 2 months